Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is an AI-driven cardiovascular diagnostics company that entered the public markets through a SPAC merger with Mana Capital Acquisition Corp, sponsored by Mana Capital LLC, which completed its IPO in 2021 and closed the de-SPAC transaction in 2022. The company operates in the healthcare sector, developing epigenomics-based tools aimed at early identification of cardiovascular disease risk. On August 5, 2026, Cardio Diagnostics filed a definitive proxy statement (DEF 14A) with the SEC in connection with an upcoming shareholder meeting, reflecting its continued status as a listed public company following the completed merger. For full filing history, sponsor data, and real-time SPAC analytics on CDIO and thousands of other transactions, sign up for a free account at SpacDesk.